CIGB-66

3 trials

Sponsors

Center for Genetic Engineering and Biotechnology (CIGB), in Havana, Center for Genetic Engineering and Biotechnology (CIGB), in Havana., Center for Genetic Engineering and Biotechnology (CIGB)

Conditions

COVID-19 COVID-19 SARS-CoV2

Phase 2

ABDALA Clinical Study

Active, not recruitingRPCEC00000346

Center for Genetic Engineering and Biotechnology (CIGB), in HavanaCOVID-19 COVID-19 SARS-CoV2

Start: 2020-12-07Updated: 2026-08-10

Phase 3

ABDALA Clinical Study - Phase III

Active, not recruitingRPCEC00000359

Center for Genetic Engineering and Biotechnology (CIGB), in Havana.COVID-19 COVID-19 SARS-CoV2

Start: 2021-03-22Target: 48290Updated: 2026-08-10

Unknown Phase

ABDALA-Intervention

Active, not recruitingRPCEC00000363

Center for Genetic Engineering and Biotechnology (CIGB)COVID-19 COVID-19 SARS-CoV2

Start: 2021-03-29Target: 124000Updated: 2026-08-10

Related Papers

A phase 3, randomised, double-blind, placebo-controlled clinical trial evaluation of the efficacy and safety of a SARS-CoV-2 recombinant spike RBD protein vaccine in adults (ABDALA-3 study).

2023-05-0514 citations

Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study).

2022-04-0951 citations